Research and Development Investment: AstraZeneca PLC vs Pfizer Inc.

AstraZeneca vs. Pfizer: R&D Investment Trends Unveiled

__timestampAstraZeneca PLCPfizer Inc.
Wednesday, January 1, 201455790000008393000000
Thursday, January 1, 201559970000007690000000
Friday, January 1, 201658900000007872000000
Sunday, January 1, 201757570000007657000000
Monday, January 1, 201859320000008006000000
Tuesday, January 1, 201959580000008650000000
Wednesday, January 1, 202059910000009405000000
Friday, January 1, 2021973600000013829000000
Saturday, January 1, 2022976200000011428000000
Sunday, January 1, 20231101500000010679000000
Loading chart...

Data in motion

A Decade of Innovation: AstraZeneca vs. Pfizer

A Comparative Analysis of R&D Investments

In the ever-evolving pharmaceutical industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, AstraZeneca PLC and Pfizer Inc. have been at the forefront of this race. From 2014 to 2023, Pfizer consistently outpaced AstraZeneca in R&D spending, with an average annual investment of approximately $9.4 billion, compared to AstraZeneca's $7.2 billion. However, AstraZeneca's R&D expenditure surged by 95% from 2017 to 2023, peaking at $10.9 billion in 2023, reflecting its commitment to innovation. Meanwhile, Pfizer's R&D spending reached its zenith in 2021 at $13.8 billion, driven by its COVID-19 vaccine development. This data underscores the dynamic nature of pharmaceutical R&D, where strategic investments can lead to groundbreaking advancements and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025